111266-27-4

Basic information

• Product Name: (S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid
• Synonyms: (S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid;(2S)-2-Methylbutanedioic acid 4-methyl ester;(2S)-Methylbutanedioic acid 4-methyl ester;(S)-Methoxy-2-methyl-4-oxobutanoic acid
• CAS NO: 111266-27-4
• Molecular Formula: C₆H₁₀O₄
• Molecular Weight: 146.1412
• Mol File: 111266-27-4.mol

Chemical Properties

• Boiling Point: 248.8±23.0 °C(Predicted)
• Appearance: /
• Density: 1.159
• Storage Temp.: 2-8°C
• PKA: 4.46±0.23(Predicted)
• CAS DataBase Reference: (S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid(111266-27-4)
• EPA Substance Registry System: (S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid(111266-27-4)

Safety Data

• Hazardous Substances Data: 111266-27-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid is used as a research chemical for studying the effects of psychoactive substances on the central nervous system. Its structural similarity to MDPV allows scientists to explore the mechanisms of action and potential therapeutic applications of cathinone-class drugs.
Used in Forensic Toxicology:
In forensic toxicology, (S)-MOMBA is utilized as a reference compound for the identification and analysis of designer drugs in biological samples. This aids in the detection and quantification of abused substances, contributing to the understanding of drug abuse patterns and the development of effective intervention strategies.
Used in Drug Policy and Regulation:
(S)-4-Methoxy-2-Methyl-4-oxobutanoic Acid serves as a benchmark for the development and enforcement of drug policies and regulations. Understanding the properties and effects of (S)-MOMBA can inform the creation of guidelines and restrictions to control the distribution and use of potentially harmful psychoactive substances.

Upstream product

• 1604-11-1 (S)-dimethyl 2-methylsuccinate 
• 67-56-1 methanol 
• 4100-80-5 2-methylsuccinic anhydride 
• 7338-27-4 4-methoxy-2-methylene-4-oxobutanoic acid 
• 97-65-4 2-methylenesuccinic acid 
• 617-54-9 citraconic acid dimethyl ester 
• 498-23-7 citraconic acid 
• 22644-27-5 (R)-methylsuccinic acid dimethyl ester 
• 143225-23-4 2(R)-Methyl-4-Benzyl Succinate 
• 3641-51-8 2-(R)-methylsuccinic acid 
• 498-21-5 2-methylbutanedioic acid 
• 21307-96-0 methyl 2-methylsuccinate 
• 623-43-8 crotonic acid methyl ester 

Downstream Products

• 143225-23-4 2(R)-Methyl-4-Benzyl Succinate 
• 185836-75-3 (R)-3-tert-butyloxycarbonyl-2-methylpropanoic acid 
• 1224397-35-6 (R)-3-methyl-4-oxo-4-(3-(trifluoromethyl)benzylamino)butyric acid methyl ester 
• 1227363-72-5 C₃₅H₄₀N₂O₉ 
• 620172-41-0 methyl (3S)-4-{[tert-butyl(diphenyl)silyl]oxy}-3-methylbutanoate 
• 173209-00-2 (3S)-4-{[tert-butyl(diphenyl)silyl]oxy}-3-methylbutan-1-ol 
• 64190-48-3 (S)-3-methyl-4-butanolide 
• 138306-24-8 methyl (3S)-4-hydroxy-3-methylbutanoate 
• 1432125-13-7 methyl 4-(2-{4-[({2-[(3-{[(2-{[(2R)-4-methoxy-2-methyl-4-oxobutanoyl](methyl)amino}ethyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoate 
• 1384132-79-9 (R)-(5-bromo-3-methylpent-1-ynyl)benzene 
• 1174194-07-0 (R)-3-methyl-5-phenylpent-4-yn-1-ol 
• 1351949-97-7 C₃₂H₄₄N₆O₆ 

Relevant articles and documents

Enantioselective Formal C?H Conjugate Addition of Acetanilides to β-Substituted Acrylates by Chiral Iridium Catalysts

The Ir-catalyzed enantioselective reaction of substituted acetanilides with β-substituted α,β-unsaturated esters provided chiral 3,3-disubstituted propanoates in high yield with good-to-excellent enantiomeric excess (up to 99 % ee). This transformation, i

A CHEMOENZYMATIC SYNTHESIS OF THE C10-C19 MOIETY OF FK506

The strategy used in the synthesis of the C10-C19 segment of FK506 is described.

Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696

LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.

Modular 1,1′-Ferrocenediyl-cored P-Stereogenic Diphosphines: ′′JDayPhos′′ Series and its Use in Rhodium(I)-Catalyzed Hydrogenation

A novel ferrocene-based P-stereogenic diphospine ligand series dubbed JDayPhos was developed, which rhodium(I) complexes of some of its members exhibited excellent enantioselectivity (up to >99% ee) and high activity in asymmetric hydrogenation of β-unsubstituted or -substituted itaconates and α-methylene-γ-oxo-carboxylates. (Figure presented.).

CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES

The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

SPIROBENZYLAMINE-PHOSPHINE, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7'-diarylphosphino-1, 1'-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.

Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof

The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7′-diarylphosphino-1,1′-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.

A three-enzyme system involving an ene-reductase for generating valuable chiral building blocks

The use of ene-reductase (ERED) enzymes for the asymmetric reduction of olefins offers a green, renewable alternative to metal-catalysed asymmetric reduction. We report herein the first example of an ERED-catalysed enantiospecific reduction carried out at large scale using a carbonyl reductase (CRED) enzyme in the cofactor recycle. This reaction has been paired with a hydrolase-mediated regioselective ester hydrolysis to generate a valuable chiral building block using a straightforward one-pot process. Copyright

A convergent approach to (-)-callystatin a based on local symmetry

The key is symmetry! A convergent synthetic approach of the highly cytotoxic natural product (-)-callystatin A was developed assembling three fragments through Julia-Kocienski olefination and Stille cross-coupling. The new strategy relies on a pivotal local symmetry of the target molecule. In this preliminary study, particular attention was devoted to facilitate the catalytic enantiocontrol of strategic stereogenic centers present in each of the fragments (see scheme). Copyright

Enantioselective hydrogenation of α-substituted acrylic acids catalyzed by iridium complexes with chiral spiro aminophosphine ligands

Highly active: Iridium complexes with chiral spiro aminophosphine ligands were synthesized and applied as catalysts for the asymmetric hydrogenation of α-substituted acrylic acids (see scheme). The complexes were highly active catalysts, showing turnover frequencies of up to 6000 h-1, and catalyst loadings could be reduced to 0.01 mol %. Copyright